Trending Topics

Trending Topics

111 Trending Topics found

MSK Kids Experts to Present Notable Research at the International Society of Paediatric Oncology’s 2019 Annual Meeting

Pediatric oncologists from around the world will gather in Lyon, France, from October 23 through 26, for the International Society of Paediatric Oncology’s annual meeting. Featuring new research and important discoveries — many led by MSK Kids researchers — the meeting will highlight the latest in the fields of pediatric oncology, including blood cancer, sarcoma, Wilms’ tumor, genomics, radiation oncology, and neuroblastoma.

  • Tuesday, October 22, 2019

Memorial Sloan Kettering’s Scott Lowe Elected to Prestigious National Academy of Medicine

Scott W. Lowe, PhD, Chair of the Cancer Biology and Genetics Program at the Sloan Kettering Institute (SKI), Howard Hughes Medical Institute Investigator, and Chair of the Geoffrey Beene Cancer Research Center, has been elected to the National Academy of Medicine (NAM), one of the highest honors bestowed upon scientists worldwide.

  • Monday, October 21, 2019

FDA Grants Breakthrough Therapy Designation to Cobimetinib for MEK Inhibition in Histiocytic Neoplasms, Research Led by MSK

Memorial Sloan Kettering Cancer Center (MSK) announced today that the US Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation to cobimetinib in treatment of patients with histiocytic neoplasms (HN) (Erdheim-Chester Disease, Rosai-Dorfman, Langerhans Histiocytosis), who do not harbor the BRAF V600 mutation. Cobimetinib is an oral inhibitor of MEK1 and MEK2 currently approved to treat melanoma. This designation was granted based on data submitted by MSK, in collaboration with Genentech, a member of the Roche Group, from a phase II trial of single-agent cobimetinib for adults with histiocytic disorders (published in Nature in March 2019 by Eli Diamond, MD; Omar Abdel-Wahab, MD; and David Hyman, MD).

  • Wednesday, October 2, 2019

ASTRO News: Adding Immunotherapy to Chemoradiation Decreases Local and Distant Recurrence of NSCLC

A new analysis of survival data for the randomized, phase III PACIFIC trial finds adding the immunotherapy cancer drug durvalumab to radiation and chemotherapy significantly decreased the recurrence of lung cancer both in the chest area and in distant sites outside the chest. The updated PACIFIC trial data will be presented at the 61st Annual Meeting of the American Society for Radiation Oncology (ASTRO), by Andreas Rimner, MD, radiation oncologist, Memorial Sloan Kettering Cancer Center.

  • Monday, September 16, 2019

Promising Data for RET Fusion-Positive Lung Cancer Patients with Targeted Therapy, Selpercatinib, Presented at the 2019 World Congress on Lung Cancer

Selpercatinib (also known as LOXO-292) is a highly selective RET inhibitor with activity against diverse RET fusions, activating RET mutations and brain metastasis. Phase 1/2 data from the LIBRETTO-001 trial presented at the IASLC 2019 World Conference on Lung Cancer demonstrates selpercatinib’s marked antitumor activity in RET fusion-position non-small cell lung cancer (NSCLC) patients. These findings, presented by Alexander Drilon, MD, principal investigator and Research Director of Early Drug Development at Memorial Sloan Kettering Cancer Center, will form the basis of an US Food and Drug Administration new drug application submission.

  • Monday, September 9, 2019

New Study Examines Wilms’ Tumor Relapse and May Give Clues to about Which Other Childhood Cancers Could Relapse

Today, researchers from MSK Kids at Memorial Sloan Kettering Cancer Center (MSK) published results that examine elevated levels of a protein called prohibitin in the urine and tumors of children with Wilms’ tumors. Their findings could help doctors identify children who are at risk for disease recurrence and precisely tailor treatment to overcome drug resistance.

  • Thursday, August 8, 2019

Memorial Sloan Kettering Among the Top “Best Hospitals” for Cancer Care and Ranked First in Gynecology by U.S News & World Report

Memorial Sloan Kettering Cancer Center (MSK) has been ranked as the number two hospital for cancer care in the nation, according to U.S. News & World Report in its annual listing of Best Hospitals. Since the inception of the rankings 30 years ago, MSK has held either the first or second spot each year for cancer care. MSK was also ranked first in gynecology.

  • Tuesday, July 30, 2019

Cracking a Code: Landmark Prospective Study Helps Researchers Better Understand Which MGUS Patients Will Progress to a Multiple Myeloma Diagnosis

Memorial Sloan Kettering Cancer Center (MSK) researchers published new results that found that individuals with low-risk or intermediate-risk myeloma precursor disease known as monoclonal gammopathy of undetermined significance (MGUS) can convert to high-risk MGUS and progress to multiple myeloma within a five-year window. This research clinically supports recommendations for annual blood tests for all individuals diagnosed with MGUS along with re-assessments of a patient’s clinical-risk status. Their research was published today online in JAMA Oncology.

  • Thursday, July 18, 2019

Surviving with Pride: Obstacles and Opportunities for LGBTQ+ Cancer Survivors

Today is the fourth anniversary of same-sex marriage being legalized in the United States. Today also marks the start of WorldPride, which celebrates the progress made toward LGBTQ+ equality while underscoring changes still needed.

  • Thursday, June 27, 2019

MSK-ACCESS Receives New York State Approval for New Molecular Assay

Memorial Sloan Kettering Cancer Center (MSK) today announced that the New York State Department of Health has issued approval for a new molecular assay, Analysis of Circulating cfDNA to Evaluate Somatic Status (MSK-ACCESS).  MSK-ACCESS was developed within the Marie-Josee and Henry R. Kravis Center for Molecular Oncology (CMO) and the test has been clinically validated and implemented by members of MSK’s Molecular Diagnostics Service.

  • Tuesday, June 11, 2019